Tag Archive for: PARP inhibitor
Phase 1/2 For a New PARP1 Inhibitor: EIK1004 (IMP1707) For mCRPC
/0 Comments/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxPARP Inhibitors in Prostate Cancer: Navigating the Complexities of DNA Repair
/0 Comments/in Review/by MaxAMPLITUDE phase 3 Study for Metastatic Castration-Sensitive Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC AI ai in healthcare alphafold antibody-drug conjugate apalutamide ASCO 2025 ATM bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy CAR-T clinical trial clinical trials crispr CYP11A1 inhibitor darolutamide drug repurposing drug resistance enzalutamide HRR immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus PARP inhibitor personalized medicine Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data theranostics
Latest Posts
- Newsletter 31/2025 August 3, 2025
- Preclinical Advances in Sequencing CDK4/6 and PARP Inhibitors August 2, 2025
- UPDATE 2: More Data About ATNM-400 Antibody Radioconjugate Therapy August 1, 2025
- New Combination Therapy Shows Potential for Treating MYC-Driven Cancers August 1, 2025